IDL Biotech Q3: Temporary sales drop
Research Note
2019-10-22
09:55
IDL’s third quarter was characterized by weaker sales than expected due to issues related to its former distributor for the Indonesian market. Consequently, EBIT also came in below our estimates. We comment on today’s report and the announcement of a new distributor for the Indonesian market.
LS
Ludvig Svensson
Disclosures and disclaimers